TheBodyPro

Can dolutegravir/lamivudine be just as effective in people with archival M184V/I as it is in everyone else? A new #study published in @CIDJournal gets us as close as we’ve ever been to a firm answer: bit.ly/3MXI4HP

#HIV #Research #Medicine

As people with #HIV live longer on viral suppression, parkinsonism‑like motor symptoms are increasingly recognized and may affect quality of life. A recent review in @TheLancet highlights why awareness of these changes matters for #aging with HIV: bit.ly/46RJM4f

Recorded during a pivotal moment for #HIV care, @UNC_ID's Dr. Wohl unpacks the top #clinical and policy developments shaping the field, and what they mean for prevention, treatment, and equity moving forward.

A must-listen for HIV clinicians: bit.ly/40k8Lta

#HIVCare

New #data affirm the value of #pneumonia and herpes zoster #vaccination for particular subsets of people living w/ #HIV — and of the continued relevance of these infectious diseases.

Dr. Young shares the three key #clinical lessons #HCPs need to know: bit.ly/4sQ96Bc

A two-year #study comparing two forms of #PrEp found small but significant differences in BMD impact. The findings provide a golden opportunity for #HCPs to revisit what we know about BMD, and how we can best approach conversations with our patients: bit.ly/4nMV809

#HIV